[go: up one dir, main page]

PE20050631A1 - Compuestos derivados de amina como inhibidores de la reabsorcion de serotonina y de noradrenalina - Google Patents

Compuestos derivados de amina como inhibidores de la reabsorcion de serotonina y de noradrenalina

Info

Publication number
PE20050631A1
PE20050631A1 PE2004000590A PE2004000590A PE20050631A1 PE 20050631 A1 PE20050631 A1 PE 20050631A1 PE 2004000590 A PE2004000590 A PE 2004000590A PE 2004000590 A PE2004000590 A PE 2004000590A PE 20050631 A1 PE20050631 A1 PE 20050631A1
Authority
PE
Peru
Prior art keywords
alkyl
serotonin
inhibitors
compounds
amine
Prior art date
Application number
PE2004000590A
Other languages
English (en)
Inventor
Deborah Jane Lovering
Alan Stobie
Gavin Alistair Whitlock
Michael Jonathan Fray
Paul Vincent Fish
Florian Wakenhut
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050631A1 publication Critical patent/PE20050631A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFEIERE A COMPUESTOS DE FORMULA (I), EN DONDE R1 ES H, -C(X)Y, ENTRE OTROS; R2 ES ARILO, HETEROARILO, COMO UN GRUPO FENILO, NAFTILO O QUINOLINILO, OPCIONALMENTE SUSTITUIDOS POR ALQUILO O ALCOXI(C1-C8), OH, HALO, CF3, ENTRE OTROS; R3 ES ALQUILO(C1-C6), CICLOALQUILO(C3-C6), CICLOALQUILO(C3-C6)-ALQUILO(C1-C3), FENILO-CH2- O NAFTILO-CH2-; X ES S U O, Y ES H, ALQUILO(C1-C6), ENTRE OTROS; n ES 1 O 2, SIEMPRE Y CUANDO n SEA 1, m SEA O,1 Y SI n ES 2, m ES 0, Y SI m ES 0, ENTONCES * ES UN CENTRO QUIRAL. SON COMPUESTOS PREFERIDOS: 2,3-DICLORO-N-ISOBUTIL-N-[(3S)-PIRROLIDIN-3-IL]BENZAMIDA, N-(2-NAFTILMETIL)-N-[(3S)-PIRROLIDIN-3-IL]BENZAMIDA, ISOBUTIL-PIRROLIDIN-3-IL-AMIDA DE ACIDO NAFTALENO-1-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA REABSORCION DE LA SEROTONINA COMO DE LA NORADRENALINA POR LO QUE SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS URINARIOS COMO INCONTINENCIA URINARIA, DEPRESION, DOLOR, EYACULACION PRECOZ, ADHD O FIBROMIALGIA
PE2004000590A 2003-06-17 2004-06-14 Compuestos derivados de amina como inhibidores de la reabsorcion de serotonina y de noradrenalina PE20050631A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
US49312603P 2003-08-06 2003-08-06

Publications (1)

Publication Number Publication Date
PE20050631A1 true PE20050631A1 (es) 2005-09-14

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000590A PE20050631A1 (es) 2003-06-17 2004-06-14 Compuestos derivados de amina como inhibidores de la reabsorcion de serotonina y de noradrenalina

Country Status (31)

Country Link
US (2) US7378436B2 (es)
EP (1) EP1638933B1 (es)
JP (1) JP4137159B2 (es)
KR (1) KR100803796B1 (es)
AP (1) AP2005003467A0 (es)
AR (1) AR044715A1 (es)
AT (1) ATE398107T1 (es)
AU (1) AU2004247487B2 (es)
BR (1) BRPI0411594A (es)
CA (1) CA2530159C (es)
CY (1) CY1110434T1 (es)
DE (1) DE602004014372D1 (es)
DK (1) DK1638933T3 (es)
EA (1) EA009881B1 (es)
EC (1) ECSP056232A (es)
ES (1) ES2305776T3 (es)
HR (2) HRP20050993A2 (es)
IL (1) IL172063A0 (es)
IS (1) IS8136A (es)
MA (1) MA27885A1 (es)
MX (1) MXPA05013960A (es)
NL (1) NL1026438C2 (es)
NZ (1) NZ544046A (es)
PA (1) PA8605301A1 (es)
PE (1) PE20050631A1 (es)
PL (1) PL1638933T3 (es)
PT (1) PT1638933E (es)
SI (1) SI1638933T1 (es)
TW (1) TW200505852A (es)
UY (1) UY28360A1 (es)
WO (1) WO2004110995A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255806A3 (en) * 2000-07-31 2011-06-29 Nycomed Danmark ApS Fentanyl composition for nasal administration
DK1638933T3 (da) * 2003-06-17 2008-07-28 Pfizer N-pyrrolidin-3-yl-amid-derivater som serotonin- og noradrenalin-genoptagelses inhibitorer
ES2336130T3 (es) 2004-10-18 2010-04-08 Eli Lilly And Company Derivados 1-(hetero)aril-3-amino-pirrolidina para uso como antagonistas del receptor de mglur3.
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
CA2590229A1 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
WO2006064332A1 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
TWI439452B (zh) * 2005-05-13 2014-06-01 Otsuka Pharma Co Ltd 吡咯烷化合物(二)
ES2330788T3 (es) 2005-06-02 2009-12-15 F. Hoffmann-La Roche Ag Derivados de piperidin-4-il-amida y su uso como antagonistas del subtipo 5 del receptor sst.
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
US20100056497A1 (en) * 2007-01-31 2010-03-04 Dainippon Sumitomo Pharma Co., Ltd Amide derivative
JP2010189275A (ja) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
US8263652B2 (en) 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
US7888386B2 (en) 2008-07-24 2011-02-15 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
TWI443087B (zh) 2008-11-14 2014-07-01 Theravance Inc 4-〔2-(2-氟苯氧基甲基)苯基〕哌啶化合物
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 N-置換-環状アミノ誘導体
US7994209B2 (en) * 2009-07-13 2011-08-09 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
JP5705239B2 (ja) 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての1−(2−フェノキシメチルフェニル)ピペラジン化合物
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
EP2627630B1 (en) 2010-10-11 2014-12-31 Theravance Biopharma R&D IP, LLC Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (es)
US3963745A (en) * 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2238081A1 (en) 1995-11-22 1997-05-29 S. Jane Desolms Inhibitors of farnesyl-protein transferase
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP2130538A1 (en) 2000-03-03 2009-12-09 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the delaying the onset of Alzheimer's disease
CN101230034A (zh) * 2000-03-06 2008-07-30 阿卡蒂亚药品公司 用于治疗5-羟色胺相关性疾病的氮杂环化合物
US7109199B2 (en) 2000-09-22 2006-09-19 Smithkline Beecham Corporation Pyrazolopyridines and pyrazolopyridazines as antidiabetics
CA2423315A1 (en) 2000-09-25 2002-03-28 Solange Meyer Substituted amino-aza-cycloalkanes useful against malaria
WO2003024928A2 (en) 2001-09-14 2003-03-27 Novo Nordisk A/S Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
CA2468761A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
JP2005533813A (ja) * 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ,インコーポレーテッド セロトニン受容体作用物質としてのn−置換ピペリジン誘導体
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
ES2323528T3 (es) 2002-12-20 2009-07-20 Chemocentryx, Inc. Inhibidores de la union de la quimiokina sdf-o i-tac al receptor ccxckr2.
DK1638933T3 (da) * 2003-06-17 2008-07-28 Pfizer N-pyrrolidin-3-yl-amid-derivater som serotonin- og noradrenalin-genoptagelses inhibitorer

Also Published As

Publication number Publication date
HRP20050993A2 (en) 2006-03-31
EA009881B1 (ru) 2008-04-28
WO2004110995A8 (en) 2005-04-21
CY1110434T1 (el) 2015-04-29
MXPA05013960A (es) 2006-02-24
CA2530159C (en) 2010-02-02
HRP20080339T3 (en) 2008-08-31
KR100803796B1 (ko) 2008-02-14
NL1026438C2 (nl) 2005-09-20
ES2305776T3 (es) 2008-11-01
KR20060036927A (ko) 2006-05-02
US20080306123A1 (en) 2008-12-11
US7378436B2 (en) 2008-05-27
AU2004247487B2 (en) 2010-05-20
CA2530159A1 (en) 2004-12-23
US20050137229A1 (en) 2005-06-23
TW200505852A (en) 2005-02-16
AU2004247487A1 (en) 2004-12-23
NL1026438A1 (nl) 2004-12-20
PL1638933T3 (pl) 2008-10-31
NZ544046A (en) 2009-08-28
IL172063A0 (en) 2009-02-11
JP4137159B2 (ja) 2008-08-20
AR044715A1 (es) 2005-09-21
ECSP056232A (es) 2006-04-19
ATE398107T1 (de) 2008-07-15
UY28360A1 (es) 2005-01-31
EP1638933B1 (en) 2008-06-11
EP1638933A1 (en) 2006-03-29
PA8605301A1 (es) 2005-02-04
WO2004110995A1 (en) 2004-12-23
AP2005003467A0 (en) 2006-12-31
EA200501730A1 (ru) 2006-08-25
DE602004014372D1 (de) 2008-07-24
MA27885A1 (fr) 2006-05-02
JP2006527758A (ja) 2006-12-07
IS8136A (is) 2005-11-21
PT1638933E (pt) 2008-07-22
BRPI0411594A (pt) 2006-08-29
SI1638933T1 (sl) 2008-10-31
DK1638933T3 (da) 2008-07-28

Similar Documents

Publication Publication Date Title
PE20050631A1 (es) Compuestos derivados de amina como inhibidores de la reabsorcion de serotonina y de noradrenalina
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
PE20060352A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
DE60209497D1 (de) Schmierölzusammensetzung enthaltend ein gemisch aus carboxylsäuren und aminen als rostschutzmittel
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
DK0783486T3 (da) Hidtil ukendte prostaglandinsynthaseinhibitorer
EA200900817A1 (ru) Способ получения фторметилзамещённых гетероциклических соединений
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
PE20090840A1 (es) Moleculas pequenas que contienen boro
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
PE20011067A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
AR057383A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
ECSP055910A (es) Nuevos acidos carboxilicos y sus esteres, medicamentos que contienen estos compuestos y procedimientos para su preparacion
EA200501477A1 (ru) Производные пиперидинил- и пиперазинилалкилкарбаматов, способы их получения и применение их в терапии
PE20000119A1 (es) Nuevos derivados de la eritromicina
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa
PE20091887A1 (es) Fenoxibenzamidas sustituidas
PE20040667A1 (es) Derivados de cinamida
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio

Legal Events

Date Code Title Description
FC Refusal